Florensocatib in adults with bronchiectasis: the HOPE-BE trial protocol and baseline demographic characteristics. (PubMed, ERJ Open Res) - Aug 26, 2026 - "Florensocatib (formerly known as HSK31858) is a novel reversible inhibitor of dipeptidyl peptidase 1...Significant geographical variations were seen regarding comorbidity, blood eosinophil counts and sputum bacteriology. The baseline demographic characteristics of the HOPE-BE trial may provide important clues to future therapeutic efficacy assessment in adults with bronchiectasis."
Journal • Bronchiectasis • Infectious Disease • Pulmonary Disease • Respiratory Diseases
|
|
Fang-Qiong Li; Guo-Jun Zhang; Han-Mo Liu; Huan Ye; Hui Jiang; Hui Shen; Jian-Ping Liang; Jie Cao; Jin-Li Liu; Jin-Xiang Wang; Li-Min Dong; Ling-Feng Min; Lu-Yin Sun; Nan-Shan Zhong; Rong Qiu; Wei-Jie Guan; Xin-Yu Song; Xun-Chao Liu; Yan Feng; Yan-Ming Huang; Zhang Bao; Zhi-Jun Liang; Zhi-Ren Yang
|